Experience the Future of Cryoablation with ProSense™ at CIRSE 2025
Discover groundbreaking advances in liquid nitrogen cryoablation technology at the 2025 Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Annual Meeting!
IceCure is excited to invite you to visit our booth and participate in exclusive hands-on sessions in Barcelona, Spain, from September 13–17, 2025.
Why Attend?
- Explore our ProSense™ Cryoablation System. Stop by Booth 41 to experience live demonstrations during the exhibition. Learn how our single-cryoprobe liquid nitrogen based cryoablation technology is shaping the future of interventional oncology, especially for breast cancer patients.
- Engage with Leading Experts. Attend a dedicated scientific session focused on breast cancer for interventional oncologists on Sunday, September 14th at 8:30 AM CEST. The session will include an insightful presentation on breast cancer metastatic disease by Dr. Franco Orsi.
- Participate in Hands-On Training. Join us for three practical training sessions on cold-based tumor ablation on Tuesday, September 16th. This is a great opportunity to enhance your skills with direct expert guidance
- HDT-TA 41.2 – Tumor ablation: cold-based – 08:30 – 10:00 CEST
- ST-HDT TA 43.1 – Tumor ablation: cold-based for students – 11:15 – 12:15 CEST
- HDT-TA 44.2 – Tumor ablation: cold-based – 13:00 – 14:30 CEST
- Stay Informed. Discover several abstracts featuring ProSense™, including both oral and poster presentations, with a special focus on breast cancer. Learn about clinical trials for breast cancer cryoablation in Europe, such as the PRECICE Trial.
Learn more about CIRSE 2025 and view the full program – https://cirse-summit.meta-dcr.com/cirse2025/widgets/page/cirse-2025-timetable
Don’t Miss Out—Stay Connected!
Want to schedule a meeting and receive exclusive updates about IceCure at CIRSE 2025? Complete the form on this page to receive all the details directly to your inbox.
We look forward to connecting with you in Barcelona! Let’s advance the future of cryoablation and interventional oncology together!
*The breast cancer indication for the ProSense® System is currently under review by the FDA and has not yet received marketing clearance in the US. ProSense™ is cleared for the treatment of breast cancer in the EU and other select markets. Clinical indications vary by region, please contact us for additional details.